Randomized Controlled Trial of Mobile Closed-Loop Control
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: Assess the efficacy of inControl AP, a mobile closed-loop control (CLC) system. RESEARCH DESIGN AND METHODS: This protocol, NCT02985866, is a 3-month parallel-group, multicenter, randomized unblinded trial designed to compare mobile CLC with sensor-augmented pump (SAP) therapy. Eligibility criteria were type 1 diabetes for at least 1 year, use of insulin pumps for at least 6 months, age ≥14 years, and baseline HbA1c <10.5% (91 mmol/mol). The study was designed to assess two coprimary outcomes: superiority of CLC over SAP in continuous glucose monitor (CGM)–measured time below 3.9 mmol/L and noninferiority in CGM-measured time above 10 mmol/L. RESULTS: Between November 2017 and May 2018, 127 participants were randomly assigned 1:1 to CLC (n = 65) versus SAP (n = 62); 125 participants completed the study. CGM time below 3.9 mmol/L was 5.0% at baseline and 2.4% during follow-up in the CLC group vs. 4.7% and 4.0%, respectively, in the SAP group (mean difference −1.7% [95% CI −2.4, −1.0]; P < 0.0001 for superiority). CGM time above 10 mmol/L was 40% at baseline and 34% during follow-up in the CLC group vs. 43% and 39%, respectively, in the SAP group (mean difference −3.0% [95% CI −6.1, 0.1]; P < 0.0001 for noninferiority). One severe hypoglycemic event occurred in the CLC group, which was unrelated to the study device. CONCLUSIONS: In meeting its coprimary end points, superiority of CLC over SAP in CGM-measured time below 3.9 mmol/L and noninferiority in CGM-measured time above 10 mmol/L, the study has demonstrated that mobile CLC is feasible and could offer certain usability advantages over embedded systems, provided the connectivity between system components is stable.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“One of these studies became the International Diabetes Closed-Loop (iDCL) Trial, which tested two algorithms originally designed in silico. 130,131”
From Developing the UVA/Padova Type 1 Diabetes Simulator: Modeling, Validation, Refinements, and Utility (2023) · cites this paper as [130]
In the citing paper
“all AID system pivotal trials that examined individuals 2 years old or older, including older adults, have consistently demonstrated superiority to either standard insulin delivery (or manual mode for the single-arm studies) or SAP and/or usual care (for the randomized trials)”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [211]
In the citing paper
“with consistent improvement in A1C, increase in TIR, especially overnight, as well as reduction of time spent in hypoglycemia (207-219).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [211]
In the citing paper
“with consistent improvement in A1C, increase in TIR, especially overnight, as well as reduction of time spent in hypoglycemia (207-219).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [211]
In the citing paper
“with consistent improvement in A1C, increase in TIR, especially overnight, as well as reduction of time spent in hypoglycemia (207-219).”
From 7. Diabetes Technology: Standards of Care in Diabetes—2025 (2025) · cites this paper as [211]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 Diabetes
Brown, S. A., Kovatchev, B. P., Raghinaru, D., Lum, J. W., Buckingham, B. A., Kudva, Y. C., Laffel, L. M., Levy, C. J., Pinsker, J. E., Wadwa, R. P., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1907863 · Cited by 1,030
Self-citationSafety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes
Bergenstal, R. M., Garg, S., Weinzimer, S. A., Buckingham, B. A., Bode, B. W., Tamborlane, W. V., & Kaufman, F. R. (2016) · JAMA · doi:10.1001/jama.2016.11708 · Cited by 644 · cited 1×
“being translated into clinical practice: following a pivotal trial and regulatory approval in 2017, the Medtronic MiniMed 670G is now commercially available and used clinically (4).”
MethodSelf-citationLachin, J. M., Genuth, S., Nathan, D. M., Zinman, B., Rutledge, B. N., & for the DCCT/EDIC Research Group (2008) · Diabetes · doi:10.2337/db07-1618 · Cited by 555
Weisman, A., Bai, J.-W., Cardinez, M., Kramer, C. K., & Perkins, B. A. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30167-5 · Cited by 463 · cited 2×
“study are consistentwith theexpectations for a closed-loopsystem: improved time in a target range and reduced risk/exposure tohypo-andhyperglycemia (18,19).”
BackgroundTauschmann, M., Thabit, H., Bally, L., Allen, J. M., Hartnell, S., Wilinska, M. E., Ruan, Y., Sibayan, J., Kollman, C., Cheng, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31947-0 · Cited by 440
Self-citationBekiari, E., Kitsios, K., Thabit, H., Tauschmann, M., Athanasiadou, E., Karagiannis, T., Haidich, A.-B., Hovorka, R., & Tsapas, A. (2018) · BMJ · doi:10.1136/bmj.k1310 · Cited by 437
Metrics for glycaemic control - from HbA1c to continuous glucose monitoring
Kovatchev, B. P. (2017) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.3 · Cited by 272
Self-citationGlycemic Goals in Diabetes: Trade-off Between Glycemic Control and Iatrogenic Hypoglycemia
Cryer, P. E. (2014) · Diabetes · doi:10.2337/db14-0059 · Cited by 236
Benhamou, P.-Y., Franc, S., Reznik, Y., Thivolet, C., Schaepelynck, P., Renard, E., Guerci, B., Chaillous, L., Lukas-Croisier, C., Jeandidier, N., et al. (2019) · The Lancet Digital Health · doi:10.1016/s2589-7500(19)30003-2 · Cited by 217
Modular Closed-Loop Control of Diabetes
Patek, S. D., Magni, L., Dassau, E., Hughes-Karvetski, C., Toffanin, C., De Nicolao, G., Del Favero, S., Breton, M., Man, C. D., Renard, E., et al. (2012) · IEEE Transactions on Biomedical Engineering · doi:10.1109/tbme.2012.2192930 · Cited by 180
Self-citationBreton, M. D., Cherñavvsky, D. R., Forlenza, G. P., DeBoer, M. D., Robic, J., Wadwa, R. P., Messer, L. H., Kovatchev, B. P., & Maahs, D. M. (2017) · Diabetes Care · doi:10.2337/dc17-0883 · Cited by 179 · cited 3×
“Subsequently, DiAs was used in a number of studies by.300 participants at 10 clinical centers in the U.S. and Europe (8,9), including longterm trials at home (10) and the first “stress test” of a CLC systemdthe Artificial Pancreas Ski Trial, where children with type 1 diabetes used DiAs during 5- day winter sport camp…”
BackgroundSelf-citationBeunckens, C., Molenberghs, G., & Kenward, M. G. (2005) · Clinical Trials · doi:10.1191/1740774505cn119oa · Cited by 152
Kovatchev, B., Cheng, P., Anderson, S. M., Pinsker, J. E., Boscari, F., Buckingham, B. A., Doyle, F. J., Hood, K. K., Brown, S. A., Breton, M. D., et al. (2017) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2016.0333 · Cited by 141
Self-citationPilot Studies of Wearable Outpatient Artificial Pancreas in Type 1 Diabetes
Cobelli, C., Renard, E., Kovatchev, B. P., Keith-Hynes, P., Ben Brahim, N., Place, J., Del Favero, S., Breton, M., Farret, A., Bruttomesso, D., et al. (2012) · Diabetes Care · doi:10.2337/dc12-0660 · Cited by 120
Self-citationMultinational Home Use of Closed-Loop Control Is Safe and Effective
Anderson, S. M., Raghinaru, D., Pinsker, J. E., Boscari, F., Renard, E., Buckingham, B. A., Nimri, R., Doyle, F. J., Brown, S. A., Keith-Hynes, P., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2468 · Cited by 120
Self-citationRenard, E., Farret, A., Kropff, J., Bruttomesso, D., Messori, M., Place, J., Visentin, R., Calore, R., Toffanin, C., Di Palma, F., et al. (2016) · Diabetes Care · doi:10.2337/dc16-0008 · Cited by 104
Self-citationSix-month randomized, multicenter trial of closed-loop control in type 1 diabetes
SA, B., BP, K., D, R., JW, L., BA, B., YC, K., LM, L., CJ, L., JE, P., RP, W., et al. (2020) · Yearbook of Paediatric Endocrinology · doi:10.1530/ey.17.10.13 · Cited by 95
Self-citationDel Favero, S., Boscari, F., Messori, M., Rabbone, I., Bonfanti, R., Sabbion, A., Iafusco, D., Schiaffini, R., Visentin, R., Calore, R., et al. (2016) · Diabetes Care · doi:10.2337/dc15-2815 · Cited by 94
DiAs User Interface: A Patient-Centric Interface for Mobile Artificial Pancreas Systems
Keith-Hynes, P., Guerlain, S., Mize, B., Hughes-Karvetski, C., Khan, M., McElwee-Malloy, M., & Kovatchev, B. P. (2013) · Journal of Diabetes Science and Technology · doi:10.1177/193229681300700602 · Cited by 85
Self-citationAutomated closed-loop control of diabetes: the artificial pancreas
Kovatchev, B. (2018) · Bioelectronic Medicine · doi:10.1186/s42234-018-0015-6 · Cited by 80
Self-citationDeshpande, S., Pinsker, J. E., Zavitsanou, S., Shi, D., Tompot, R., Church, M. M., ANDRE, C. C., Doyle, F. J., & Dassau, E. (2018) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2018.0278 · Cited by 64
Self-citationQing, K. Y., Wasilczuk, K. M., Ward, M. P., Phillips, E. H., Vlachos, P. P., Goergen, C. J., & Irazoqui, P. P. (2018) · Bioelectronic Medicine · doi:10.1186/s42234-018-0005-8 · Cited by 57
Cited by
7. Diabetes Technology: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s007 · Cited by 358
7. Diabetes Technology: Standards of Care in Diabetes—2025
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Ekhlaspour, L., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s007 · Cited by 348
Self-citation7. Diabetes Technology: Standards of Care in Diabetes — 2023
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s007 · Cited by 301
7. Diabetes Technology: Standards of Care in Diabetes—2024
American Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Bruemmer, D., Collins, B. S., Ekhlaspour, L., Hilliard, M. E., Johnson, E. L., Khunti, K., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s007 · Cited by 281
Self-citationOne Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop Technology
Breton, M. D., & Kovatchev, B. P. (2021) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0097 · Cited by 250
Self-citation
Metadata
- Authors
- Kovatchev, B., Anderson, S. M., Raghinaru, D., Kudva, Y. C., Laffel, L. M., Levy, C., Pinsker, J. E., Wadwa, R. P., Buckingham, B., Doyle, F. J., Brown, S. A., Church, M. M., Dadlani, V., Dassau, E., Ekhlaspour, L., Forlenza, G. P., Isganaitis, E., Lam, D. W., Lum, J., Beck, R. W., iDCL Study Group, Kovatchev, B., Anderson, S. M., Brown, S. A., Emory, E., Voelmle, M., Conshafter, K., Morris, K., Oliveri, M., Mitchell, H., Calvo, K., Wakeman, C., Breton, M., Laffel, L. M., Isganaitis, E., Ambler-Osborn, L., Flint, E., Schultz, A., Kim, K., Pinsker, J. E., Church, M. M., Andre, C., Levy, C., Lam, D. W., O’Malley, G., Levister, C., Ogyaadu, S., Kudva, Y. C., Dadlani, V., Simha, V., McCrady-Spitzer, S., Reid, C., Wadwa, R. P., Forlenza, G. P., Jost, E., Messer, L., Berget, C., Towers, L., Buckingham, B., Ekhlaspour, L., Hsu, L., Loebner, S., Doyle, F. J., Dassau, E., Lum, J., Beck, R. W., Campos, T., Passman, S., Murphy, C., Patibandla, N., Raghinaru, D., & Kollman, C.
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2020-01-14
- Volume
- 43
- Issue
- 3
- Pages
- 607-615
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC7035585
- OpenAlex
- W3000000785
- Semantic Scholar
- 1fb5a32cad7ab49b4e9b868744caaab314a5e229
- Cited by
- 60
- References
- 23
- Citations by year
- 2026: 4 · 2025: 6 · 2024: 11 · 2023: 11 · 2022: 8 · 2021: 12 · 2020: 8
- FWCI
- 7.35
- Type
- journal article
- Language
- en
- Update notices
- correction (2020-06-01)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institute of Diabetes and Digestive and Kidney Diseases (UC4-DK-108483)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Education
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- type 1 diabetes, sensor-augmented pump, continuous glucose monitoring, insulin pump therapy, hypoglycemia, hyperglycemia, glycemic control, non-inferiority
- MeSH terms
- Adolescent, Adult, Aged, Blood Glucose, Diabetes Mellitus, Type 1, Female, Humans, Hypoglycemic Agents, Insulin, Insulin Infusion Systems, Male, Middle Aged, United States, Blood Glucose Self-Monitoring, Biosensing Techniques, Telemedicine, Pancreas, Artificial, Young Adult, Insulin, Regular, Human, Mobile Applications
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.